Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Immunosuppressive Cancer Treatment Tied to Worse COVID-19 Outcomes
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Lois M.
Received at Testimonial Submit Form Saturday, January 28, 2023 at 07:33 AM PST
(Unedited)

Hi, my name is Lois. I am 73 years old and have always been in good health until my late 60’s I started having a lot of joint pain swelling of joints in my fingers but the knee pain was the worst. Doctor said I needed knee surgery because my left knee was bone on bone.

After trying so many supplements I came across Ezorb and decided to order the calcium. I have been taking it now for about 5 months I don’t have the knee pain night now but I am still having the shoulder pain. I am hoping that it will eventually leave too.

Thank you for this wonderful supplement it has made life easier.

Letter II: From Barbara A. P.
Received at Testimonial Submit Form Friday, October 28, 2022 at 04:05 AM PDT
(Unedited)

Hi, my name is Barbara. I was diagnosed with bone spurs in several of my neck vertebrae. A friend told me about EZORB.

After trying this partular type of Calcium, I noticed relief from the constant pain I have been in since a 1991 car accident that caused my neck damage (i.e., compressed discs that have rubbed on each other for so long that- spurs have formed on the 1-2 and the 5-6 discs).

Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public.

People with cancer receiving immunotherapy (IO) or other anticancer treatments are at increased risk for adverse COVID-19 outcomes if they are also receiving immunosuppressive therapy, suggests a registry-based cohort study.

“This represents the largest cohort with comprehensive clinical and biological data of patients with cancer and COVID-19 treated with IO reported so far, helping to evaluate the influence of IO and immunosuppression on patient outcomes and cytokine storm,” say the researchers who drew on the COVID-19 and Cancer Consortium (CCC19) registry for their study.

Of the 12,046 patients (median age 65 years) with a current or past diagnosis of cancer and laboratory-confirmed SARS-CoV-2 infection reported to the registry between March 2020 and May 2022, 5.0% had received IO within 3 months before the COVID-19 diagnosis, 35.9% had received non-IO agents, and 59.1% had not received any anticancer therapy.

In the overall cohort, there was no significant difference between the IO, non-IO, and untreated groups with respect to the severity of COVID-19 or incidence of cytokine storm.

But a multivariable analysis stratified by baseline immunosuppression showed that patients receiving both IO and immunosuppressive therapy had a significantly higher risk for poor COVID-19 outcomes and cytokine storm, at adjusted odds ratios (ORs) relative to untreated patients of 3.33 and 4.41, respectively.

The risks for adverse COVID-19 outcomes and for developing cytokine storm were also increased, albeit to a lesser degree, for individuals with baseline immunosuppression receiving non-IO therapies, with significant adjusted ORs of 1.79 and 2.32, respectively.

No such associations were observed among participants without baseline immunosuppression, note Toni Choueiri, from Dana-Farber Cancer Institute in Boston, Massachusetts, USA, and co-investigators in JAMA Oncology.

And they add that the results were similar in the subset of patients with active cancer and in sensitivity analysis excluding those “who received a combination of cytotoxic chemotherapy and PD-(L)1 inhibitors in the IO group.”

Of note, vaccination against SARS-CoV-2 appeared to attenuate the risk for adverse COVID-19 outcomes and cytokine storm, such that there was no significant difference between individuals with and without baseline immunosuppression.

“The findings of this study help better characterize the association of IO with poor COVID-19 outcomes in relation to immunosuppression among patients with cancer, and also suggest that these agents are relatively safe to use among immunocompetent patients even during peaks of the pandemic,” conclude Choueiri and colleagues.

Original research was published in JAMA Oncol 2022; doi:10.1001/jamaoncol.2022.5357.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index